Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Naoki Ishiguro, Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2020) Factors influencing physician decisions to discontinue treatment after onset of liver dysfunction: Post-hoc analysis of an all-case post-marketing surveillance study of iguratimod. Modern Rheumatology 30:4, pages 633-639.
Read now
Read now
Naoki Ishiguro, Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2020) Investigation of the predictors of the response to Iguratimod therapy: A post-hoc analysis of post-marketing surveillance study. Modern Rheumatology 30:4, pages 626-632.
Read now
Read now
Hideto Kameda, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil Graham & Yoshiya Tanaka. (2020) Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). Modern Rheumatology 30:2, pages 239-248.
Read now
Read now
Koichiro Ishikawa & Junichiro Ishikawa. (2019) Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Modern Rheumatology 29:3, pages 418-429.
Read now
Read now
Tsuneyo Mimori, Masayoshi Harigai, Tatsuya Atsumi, Takao Fujii, Masataka Kuwana, Hiroaki Matsuno, Shigeki Momohara, Syuji Takei, Naoto Tamura, Yoshinari Takasaki, Kazuhiko Yamamoto, Satoshi Ikeuchi, Satoru Kushimoto & Takao Koike. (2019) Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study. Modern Rheumatology 29:2, pages 314-323.
Read now
Read now
Y Luo, N Zheng & R Wu. (2018) Is iguratimod effective in refractory axial spondyloarthritis?. Scandinavian Journal of Rheumatology 47:6, pages 518-520.
Read now
Read now
Ryosuke Kamei, Masanori Kono, Yukiko Iwasaki, Hirofumi Shoda, Kanae Kubo, Keishi Fujio & Kazuhiko Yamamoto. (2017) Iguratimod-induced acute interstitial pneumonia with hypogammaglobulinemia in a rheumatoid arthritis patient. Modern Rheumatology Case Reports 1:2, pages 54-59.
Read now
Read now
Articles from other publishers (20)
Marjan Assefi, Kai-Uwe Lewandrowski, Morgan Lorio, Rossano Kepler Alvim Fiorelli, Stefan Landgraeber & Alireza Sharafshah. (2023) Network-Based In Silico Analysis of New Combinations of Modern Drug Targets with Methotrexate for Response-Based Treatment of Rheumatoid Arthritis. Journal of Personalized Medicine 13:11, pages 1550.
Crossref
Crossref
Ting Xue, Xiaomei Kong & Liang Ma. (2023) Trends in the Epidemiology of Pneumocystis Pneumonia in Immunocompromised Patients without HIV Infection. Journal of Fungi 9:8, pages 812.
Crossref
Crossref
Qingran Yan, Bei Liu, Jieying Wang, Hanlin Yin, Qianqian Li & Liangjing Lu. (2023) Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer. Frontiers in Medicine 10.
Crossref
Crossref
Hiroshi Takei, Satoshi Takanashi, Kotaro Otomo, Hironari Hanaoka, Jun Kikuchi, Kunihiro Yamaoka, Keiko Yoshimoto, Takayuki Abe, Tsutomu Takeuchi & Yuko Kaneko. (2022) Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment. Modern Rheumatology.
Crossref
Crossref
Kaue Franco Malange, Juliana M. Navia-Pelaez, Elayne Vieira Dias, Julia Borges Paes Lemes, Soo-Ho Choi, Gilson Goncalves Dos Santos, Tony L. Yaksh & Maripat Corr. (2022) Macrophages and glial cells: Innate immune drivers of inflammatory arthritic pain perception from peripheral joints to the central nervous system. Frontiers in Pain Research 3.
Crossref
Crossref
Dan Ouyang, Yuan Zhi Ma, Jie Zou, Yong Long Wang, Zheng Chen, Yu Ying Yang, Bin Zou, Xin Li & Jian Zhong Cao. (2022) Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Wentian Lu, Zhichun Liu & Leixi Xue. (2022) Allergic Skin Rash Caused by Iguratimod: A Report of Two Cases. Cureus.
Crossref
Crossref
Kai Shibata, Akiko Yoshimura, Satoshi Ikeuchi & Mika Ishii. (2021) Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: Post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations. PLOS ONE 16:7, pages e0253513.
Crossref
Crossref
L.-J. Chen, Y.-J. Zhou, Z.-H. Wen, F. Tian & J.-Y. Li. (2020) Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritisWirksamkeit und Sicherheit von Iguratimod in Kombination mit Methotrexat vs. Methotrexat allein bei rheumatoider Arthritis. Zeitschrift für Rheumatologie 80:5, pages 432-446.
Crossref
Crossref
Yuji Nozaki. (2021) Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World. Life 11:5, pages 457.
Crossref
Crossref
Rong Mu, Chun Li, Xiaomei Li, Yao Ke, Ling Zhao, Lin Chen, Rui Wu, Zhenbiao Wu, Xiaoxia Zuo, Yanli Xie, Jinwei Chen, Wei Wei, Yi Liu, Zhijun Li, Lie Dai, Lingyun Sun, Xiangyuan Liu & Zhanguo Li. (2021) Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. The Lancet Regional Health - Western Pacific 10, pages 100128.
Crossref
Crossref
Satoshi Mizutani, Hitoshi Kodera, Yoshiko Sato, Toshihiro Nanki, Shunji Yoshida & Hidekata Yasuoka. (2020) Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. Clinical Rheumatology 40:1, pages 123-132.
Crossref
Crossref
Asuka Inoue, Yuji Nozaki, Yasuaki Hirooka, Koji Kinoshita, Yasutaka Chiba, Masanori Funauchi & Itaru Matsumura. (2020) The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care. Life 10:11, pages 261.
Crossref
Crossref
Sisi Xie, Shu Li, Jing Tian & Fen Li. (2020) Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape. Frontiers in Pharmacology 11.
Crossref
Crossref
Huihui Jiang, Hongyan Gao, Qin Wang, Miao Wang & Bin Wu. (2020) Molecular mechanisms and clinical application of Iguratimod: A review. Biomedicine & Pharmacotherapy 122, pages 109704.
Crossref
Crossref
Yan Ye, Mei Liu, Longhai Tang, Fang Du, Yuanhua Liu, Pei Hao, Qiong Fu, Qiang Guo, Qingran Yan, Xiaoming Zhang & Chunde Bao. (2019) Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. Arthritis Research & Therapy 21:1.
Crossref
Crossref
Jie Li, Jun Bao, Jian Zeng, Aizhu Yan, Chunqiu Zhao & Qiang Shu. (2019) Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology. Bone Research 7:1.
Crossref
Crossref
Xiao-li Li, Xiao-Chang Liu, Yu-Lin Song, Ru-Tao Hong & Hai Shi. (2018) Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature. BMC Gastroenterology 18:1.
Crossref
Crossref
Guangrui Li, Ryo Yamasaki, Mei Fang, Katsuhisa Masaki, Hirofumi Ochi, Takuya Matsushita & Jun-ichi Kira. (2018) Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway. Scientific Reports 8:1.
Crossref
Crossref
Atsushi Hashimoto, Shiori Suto, Kouichiro Horie, Hidefumi Fukuda, Shinichi Nogi, Kanako Iwata, Hirotaka Tsuno, Hideki Ogihara, Misato Kawakami, Akiko Komiya, Hiroshi Furukawa, Toshihiro Matsui & Shigeto Tohma. (2017) Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis. International Journal of Rheumatology 2017, pages 1-8.
Crossref
Crossref